Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 years or older.
• People with prostate cancer (specifically a type called adenocarcinoma) that has been confirmed by a tissue sample (biopsy) taken within the last 9 months, where the cancer is contained within the prostate gland.
• People who are on active surveillance for prostate cancer and have shown signs of the disease progressing, with a biopsy taken within the last 9 months.
• People whose biopsy was done using a specific method that combines at least 8 tissue samples from across the prostate plus additional targeted samples guided by MRI imaging.
• People with a cancer grade called Gleason Score 7 (either 3+4 or 4+3).
• People with a PSA blood test result of 15 or below.
• People whose cancer lesion measured on a specific type of MRI scan is smaller than 1.5 cm³ in volume.
• People who have had recent imaging (CT, MRI, or PET scan of the pelvis within the last 6 months) confirming the cancer has not spread beyond the prostate.
• People where the area to be treated measures less than 50 cm³ as seen on ultrasound or MRI.
• People who are in good general health and able to carry out normal daily activities with little to no limitation (confirm with trial site).
• People with a life expectancy of at least 36 months.
• People with adequate bone marrow, kidney, and liver function, as confirmed by blood tests meeting specific thresholds.
• People who have read, understood, and signed the informed consent form.

Who may not be able to join:

• People whose cancer has spread beyond the prostate, into nearby lymph nodes, or to other parts of the body.
• People whose MRI scan shows any signs that the cancer may be growing through the outer wall of the prostate.
• People with a significant suspicious lesion on the opposite side of the prostate to the treatment area on MRI, even if a biopsy of that area came back negative.
• People with a high amount of low-grade cancer (Grade Group 1) on the opposite side of the prostate from the treatment area, outside the planned treatment zone (confirm with trial site for specific definition).
• People who have previously had surgery to remove the prostate, radiation to the pelvis, a procedure called TURP (removal of prostate tissue), or freezing treatment (cryosurgery) of the prostate.
• People who have previously had brachytherapy (a type of internal radiation treatment).
• People who have previously received hormone therapy or chemotherapy for prostate cancer.
• People with a current or past bleeding disorder.
• People whose tumour is known to be growing into or very close to a major blood vessel near the treatment site.
• People who have taken alpha-reductase inhibitor medications (a type of prostate medication) within 90 days before joining the trial.
• People with serious ongoing health conditions, infections, mental health conditions, or other medical issues that the trial investigators determine would prevent safe participation.
• People who lack the mental capacity to give informed consent or to attend follow-up visits, as assessed by the trial investigators.
• People with a condition called porphyria, or other conditions made worse by light exposure.
• People with a known allergy or sensitivity to the light-activated drug used in this trial (verteporfin) or to porphyrin-type substances.
• People currently taking another medication that makes the skin or body sensitive to light.
• People who have taken part in another treatment-based clinical trial within the 3 months before joining, or who are currently enrolled in another therapeutic trial.
• People who cannot have an MRI scan or receive MRI contrast dye, such as those with certain metal implants, hip replacements, severely reduced kidney function, or a history of reactions to contrast dye.
• People with a known allergy to certain muscle-relaxant medications used during procedures (pancuronium bromide, atracurium, or cisatracurium).

Important: Always verify eligibility with the trial site directly before applying.